Table 4.2Diagnostic yield of initial and further diagnostic tests

StudyN patientsPrimaries identifiedPrimary tumour identified by initial tests*Treatable cancers identified by initial tests**Primary tumour identified by further tests*Treatable cancers identified by further tests**
Any presentation
Kirsten 198728658/286 (20%)--5829
Le Chevalier 1988302134/302 (44%)81not reported53not reported
Losa Gaspa 2002221175/221 (79%)13836377
Bone metastases
Alcalay 1995350109/350 (31%)8959205
Jacobsen 19972922/29 (76%)18641
Katigiri 19996460/64 (94%)4817121
Rougraff 19934036/40 (90%)34220
Simon 19864620/46 (43%)16541
*

Initial tests are defined in table 1

**

Treatable cancers defined as: breast, ovarian, germ cell, prostate, head/neck, thyroid,

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.